Findings of industry mortality experience studies are used by (re)insurers and regulators as the basis for developing liability expectations, reserve guidelines, and solvency capital requirements.
SCOR announces an innovative and efficient 3-year contingent capital facility.
Winner of the Actuarial Award in UK, 2013
Each year, in various countries, SCOR rewards the best academic work in the field of actuarial science with prizes.
SCOR Global Life, a subsidiary of SCOR SE, has entered into an innovative longevity transaction with the Netherlands-based insurer Aegon.
This is one of the first longevity transactions to be completed in continental Europe and confirms SCOR’s pioneering role in this emerging and important market.
Standard & Poor’s has raised the outlook on the “A+” rating of SCOR SE and its main subsidiaries to “positive” as, according to S&P’s statement, “capital and earnings expected to rise due to very strong ERM”.
The aims of this brochure are to provide the reader with a simple introduction to genes and genetic processes in humans and an insight as to how this rapidly developing field of science could impact on the insurance i
The aims of this brochure are to provide the reader with a simple introduction to genes and genetic processes in humans and an insight as to how this rapidly developing field of science could impact on the insurance i
The aims of this brochure are to provide the reader with a simple introduction to genes and genetic processes in humans and an insight as to how this rapidly developing field of science could impact on the insurance i
Winner of the Actuarial Award in Germany, 2013
Winner of the Actuarial Award in Germany, 2013
